Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Regado Biosciences's share price for the quarter that ended in Jun. 2016 was $0. Regado Biosciences's Shares Outstanding (EOP) for the quarter that ended in Jun. 2016 was 0.00 Mil. Therefore, Regado Biosciences's market cap for the quarter that ended in Jun. 2016 was $ Mil.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Regado Biosciences's Enterprise Value for Today is $20.07 Mil.
Regado Biosciences Market Cap Historical Data
The historical data trend for Regado Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Regado Biosciences's Market Cap
For the Biotechnology subindustry, Regado Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regado Biosciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regado Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Regado Biosciences's Market Cap falls into.
Regado Biosciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Regado Biosciences's Market Cap for the fiscal year that ended in Dec. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regado Biosciences (NAS:RGDO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Regado Biosciences Market Cap Related Terms
Thank you for viewing the detailed overview of Regado Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Regado Biosciences (Regado Biosciences) Business Description
Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. The Company is developing REG1 as an anticoagulant for use in patients with cardiovascular conditions undergoing percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGDO has been successfully added to your 